Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
NCT06026358 · Medical University of Graz · PHASE4 · withdrawn · last registry update 2024-05-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of ressources” | – | Registry record, Medical University of Graz |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SRC within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-10Results posted on the registry: Novartis Pharmaceuticals, Imatinib + Nilotinib (NCT04971226)
- 2025-02-20Results posted on the registry: Almirall, S.A., Tirbanibulin 2.5 mg ointment (NCT05741294)
- 2024-11-07Results posted on the registry: Pfizer, Bosutinib capsule + Bosutinib capsule (NCT04916769)
- 2024-09-20Results posted on the registry: Pfizer, Bosutinib capsule + Bosutinib capsule (NCT05032690)
- 2024-06-13Results posted on the registry: Loxo Oncology, Inc., Selpercatinib + Cabozantinib (NCT04211337)
- 2024-05-21Phase 3 first posted: Ascentage Pharma Group Inc., olverembatinib + Bosutinib (NCT06423911)
- 2024-03-19Also stopped (terminated): Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica, Bosutinib 400 MG Monotherapy + Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection (NCT04793399)
- 2024-03-12Results posted on the registry: Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica, Bosutinib 400 MG Monotherapy + Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection (NCT04793399)
- 2024-01-23Results posted on the registry: Almirall, S.A., Tirbanibulin ointment 1% (NCT05279131)
- 2024-01-05Also stopped (withdrawn): Hoffmann-La Roche, Pralsetinib + Cabozantinib (NCT04760288)
- 2023-11-18Phase 3 first posted: Almirall, S.A., Tirbanibulin (NCT06135415)
- 2023-07-17Results posted on the registry: M.D. Anderson Cancer Center, Bosutinib + Inotuzumab Ozogamicin (NCT02311998)
- 2023-07-17Results posted on the registry: M.D. Anderson Cancer Center, Ilorasertib (NCT02478320)
- 2023-07-17Also stopped (terminated): M.D. Anderson Cancer Center, Ilorasertib (NCT02478320)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision